Abstract: Provided herein are antibodies that specifically bind LRP5 and method of use thereof.

Abstract: There is provided herein a method for identifying and/or recovering at least one genetically encoded affinity reagent specific for a target molecule by screening using molecular display in conjunction with the sequencing of positive and negative selection pools from the screen.

Abstract: Isolated antibodies and immunoconjugates that specifically bind Frizzled receptor (FZD) 4 cysteine rich domain (CRD) comprising a light chain variable region and a heavy chain variable region, the heavy chain variable region comprising complementarity determining regions CDR-H1, CDR-H2 and CDR-H3, the light chain variable region comprising complementarity determining region CDR-L1, CDR-L2 and CDR-L3, and with the amino acid sequences of said CDRs comprising or consisting of sequences selected from sequences in Table 1a or 3a. Methods of using the antibodies and immunoconjugates are also provided.

Abstract: A hybrid guide RNA (hgRNA) comprising a proximal spacer, a distal spacer, a type II CRISPR-Cas tracrRNA, and a type V CRISPR-Cas direct repeat. Also provided herein are further multiplexed hgRNAs comprising additional direct repeats and spacers as well as methods of making and using thereof. Libraries comprising said hgRNAs or components thereof, cells, kits and reagents employed in the making or use thereof are also provided.

Abstract: Provided herein are antibodies that specifically bind LRP6 and method of use thereof.

Abstract: The invention provides novel synthetic antibodies directed against VEGF and uses thereof.

Abstract: This disclosure is directed to novel CD133-binding agents. The disclosure is also directed to uses of novel CD133-binding agents for detecting CD133-expressing cells and/or quantitating levels of cellular CD133 expression, for targeting CD133-expressing cells, for decreasing levels of CD133 in CD133-expressing cells and for treating or preventing cancer.

Abstract: The invention provides novel synthetic antibodies directed against VEGF and uses thereof.

Abstract: This disclosure is directed to novel CD133-binding agents. The disclosure is also directed to uses of novel CD133-binding agents for detecting CD133-expressing cells and/or quantitating levels of cellular CD133 expression, for targeting CD133-expressing cells, for decreasing levels of CD133 in CD133-expressing cells and for treating or preventing cancer.

Abstract: Microfluidic devices, kits systems and methods are provided for high throughput phenotypic separation of magnetically labelled cell samples. The devices and methods can be used for example to sort cells based on level of target marker and to sort screen cells, such as CRISPR screen cells and other screens with a large number of target cells, to isolate target cells and putative genetic modifiers.

Abstract: The present disclosure is directed to novel FZD5-binding agents and methods and uses thereof for treating a disease or disorder associated with aberrant expression of activity of Frizzled protein.

Abstract: A method for identifying a protein associated with a receptor-ligand interaction is described. The method comprises providing a population of engineered cells comprising a targeting library targeting specific gene expression, contacting the population of cells with a recombinant toxin fusion for sufficient time, and identifying proteins in the selection pool of cells by sequencing one or more of the nucleic acid molecule comprised in the selection pool of cells, thereby identifying the target gene. Toxin-resistant cell lines, toxin-producing cell lines, recombinant toxin fusions, probes and methods producing same, and kits thereof, are also provided.

Abstract: There is provided herein a method for identifying and/or recovering at least one genetically encoded affinity reagent specific for a target molecule by screening using molecular display in conjunction with the sequencing of positive and negative selection pools from the screen.

Abstract: The present disclosure is directed to novel FZD5-binding agents and methods and uses thereof for treating a disease or disorder associated with aberrant expression or activity of Frizzled protein.

Abstract: There is provided herein a method for identifying and/or recovering at least one genetically encoded affinity reagent specific for a target molecule by screening using molecular display in conjunction with the sequencing of positive and negative selection pools from the screen.

Abstract: This invention provides monoclonal antibodies that recognize one or more Frizzled receptors. The invention further provides methods of using such monoclonal antibodies as a therapeutic, diagnostic, and prophylactic.

Abstract: This disclosure is directed to novel CD133-binding agents. The disclosure is also directed to uses of novel CD133-binding agents for detecting CD133-expressing cells and/or quantitating levels of cellular CD133 expression, for targeting CD133-expressing cells, for decreasing levels of CD133 in CD133-expressing cells and for treating or preventing cancer.

Abstract: The invention provides novel synthetic antibodies directed against VEGF and uses thereof.

Abstract: This invention provides monoclonal antibodies that recognize one or more Frizzled receptors. The invention further provides methods of using such monoclonal antibodies as a therapeutic, diagnostic, and prophylactic.

Abstract: The present invention provides methods of identifying the presence and relative abundance of a protein in or on a cell or population of cells, with the methods comprising applying to a population of cellular proteins a collection of Fab-phage particles that contain nucleic acid encoding at least one antibody Fab fragment, wherein each of the antibody Fab fragments has a known protein to which it will bind in a specific manner. After binding is allowed to occur, those Fab-phage not bound to targets are washed away and the remaining phage are propagated in bacteria before the nucleic acid within the Fab-phage is amplified and then sequenced to determine the polynucleotide sequences of the nucleic acid molecules from the Fab-phages that bound to the cellular proteins. The nucleotide sequences of the nucleic acid molecules from the Fab-phages correlate to the coding sequences of the antibody Fab fragments that are known to bind in a specific manner to a protein.